SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Psoriasis/Chronic Inflammation
An SI Board Since February 2001
Posts SubjectMarks Bans
631 42 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
356MorphoSys / Boehringer / ICAM-1 Tuesday February 25 MUNICH -(Dow Jones)- Morphonigel bates-2/25/2003
355Roche / Chugai / MRA BASEL -(Dow Jones)- Swiss pharmaceuticals company Roche Honigel bates-2/25/2003
354oooops..... beta1, not beta2. :-) (thanks.... no wonder I couldn't findscaram(o)uche-2/23/2003
353Rick >>I was confused by your response, a couple of months ago, in the VDIcebrg-2/23/2003
352Erik: If I've understood you correctly............. You have implied that scaram(o)uche-2/23/2003
351<i>Almost everyone else viewed targeting cytokines as a waste of time. &quscaram(o)uche-2/23/2003
350<i>CYTOKINE BLOCKERS. Those small but potent messenger proteins, cytokineIcebrg-2/23/2003
349>> Perhaps his whoring days are over. << biz.yahoo.com <i>Thscaram(o)uche-2/20/2003
348<b>LFA3tip not approved, CPMP................</b> European Approvalscaram(o)uche-2/20/2003
347<<At Gel Tech, Dr. Davidson raised capital for the market launch and distrmichael_f_murphy-2/20/2003
346Neuroimmunomodulation 2002-2003;10(4):208-16 Anti-Inflammatory Effects of alphscaram(o)uche-2/19/2003
345Strange company, half way between UCLA and Amgen, if the address has anything &qscaram(o)uche-2/19/2003
344Interferons in relapsing remitting multiple sclerosis: a systematic review GrazIcebrg-2/14/2003
343Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn'Icebrg-2/12/2003
342<b>LFA3tip approved</b>............... Message 18517445 1. historscaram(o)uche-1/31/2003
341Hey, guys..... this is a file folder. Chat is discouraged. Please take it elscaram(o)uche-1/30/2003
340Tex, Believe it or not I thought about taking a LGND position, but then I rememEdscharp-1/30/2003
339Ed, I guess I'm still a glutton for punishment...still adding to my LGND posArthur Radley-1/30/2003
338Tex, Are you tired of biotechs yet? What's your next pick? <g>Edscharp-1/30/2003
337XOMA Initiates Phase II Clinical Trial with Raptiva -- Efalizumab -- in PsoriatiIcebrg-1/30/2003
336Alexion Completes Enrollment in Phase IIb Trial of Eculizumab in Rheumatoid ArthIcebrg-1/30/2003
335Well! We can kiss BTRN adios! They have no funds to fight this case in the courtArthur Radley-1/29/2003
334[ salt/Open Wound, Inc. ] BioTransplant Announces Receipt of Purported Terminatscaram(o)uche-1/29/2003
333US FDA Approves Genmab's IND to Investigate Humax-IL15 to Treat Rheumatoid Ascaram(o)uche-1/29/2003
332Arthritis drugs face safety review FDA studies possible cancer link for three drkeokalani'nui-1/28/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News